remdesivir - versus antiviral and associated therapy - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.37 [0.69, 2.72]< 10%1 study (1/-)18.2 %NAnot evaluable crucial-
clinical improvement 1.27 [0.98, 1.63]> 10%1 study (1/-)96.7 %NAnot evaluable important-
clinical improvement (14-day) 0.65 [0.44, 0.98]> 10%1 study (1/-)2.0 %NAnot evaluable important-
clinical improvement (7-day) 0.69 [0.45, 1.05]> 10%1 study (1/-)4.2 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.27 [0.98, 1.63]> 10%1 study (1/-)96.7 %NAnot evaluable important-
recovery 1.23 [0.97, 1.57]> 10%1 study (1/-)95.6 %NAnot evaluable non important-

safety endpoints 00

serious adverse events (SAE), any 1.98 [1.27, 3.11]< 10%1 study (1/-)0.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.